Webinars and Commercial Conversations — Register Now
Tuesday, December 1, 2026, 1 PM-2 PM ET
Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.
Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.
Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Interactive Product Guides
CAP TODAY Webinars
Navigating HER2 protein expression in breast cancer-October 20, 2026
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center, reviews the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis. They also discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Gain practical insights into the HER2 IHC scoring criteria. We will examine stained slides to refine the participant’s ability to apply guidelines with confidence and consistency and learn how to standardize these findings in pathology reports to facilitate high-level multidisciplinary discussions and guide precision treatment decisions.
The Value in Incorporating In-House Comprehensive Genomic Profiling into your Clinical Setting-October 1, 2026
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center, leads a presentation exploring the value of in-house CGP, offers insights into the benefits and drawbacks of incorporation, and provides information about important practical factors when considering in-house implementation of CGP.
Comprehensive genomic profiling (CGP) is a valuable tool for analyzing clinical tumor specimens. Whereas it is most often considered important for the identification of targetable alterations in advanced cancers, it is also proving useful in planning therapeutic regimens in early cancer settings, offering clinical trial enrollment and in the identification of alterations that could change a diagnosis. Integration of CGP into in-house pathology workflows requires thoughtful deliberation, but its implementation can prove very useful to the clinicians, pathologists and patients that it supports. This presentation will discuss the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
RAS in Action: From a Single Mutation to a Targeted Class-September 24, 2026
Webinar presenters Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian, and David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, explore the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Simplifying Digital Pathology: Getting Started Without a Complex Rollout-August 26, 2026
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center Department of Pathology, and Molly Epler, MHI, LSSYB, Clinical Laboratory Manager, Wexner Medical Center discuss digital pathology technology that is future-ready, yet practical for today’s laboratory needs, how Ocus M scanner is making DP more accessible, and provide perspective on where DP is headed, including how market developments (e.g. Grundium’s recent acquisition of VisioPharm) may signal broader trends.
Decoding plasma cell-rich lesions: Kappa, Lambda and beyond-July 15, 2026
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine, Department of Pathology, SOM at Johns Hopkins University, discusses how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Leukemia Immune Escape and HLA Loss of Heterozygosity: Understanding Clinical Implications for Allogeneic HCT-June 9, 2026
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP, São Paulo and CHC/UFPR in Curitiba, Brazil, examines how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.